Opus Genetics (IRD) Earnings Date, Estimates & Call Transcripts $0.80 -0.02 (-2.50%) Closing price 04/15/2025 04:00 PM EasternExtended Trading$0.82 +0.02 (+2.24%) As of 04/15/2025 07:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Earnings Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesSEC FilingsTrendsBuy This Stock Opus Genetics Earnings Summary Upcoming Q1 Earnings DateMay. 9Before Market OpensEstimatedConsensus EPS (Mar. 31) -$0.34 Actual EPS (Mar. 31) -$1.27 Missed By -$0.93 Actual Revenue (Mar. 31) $3.40MOpus Genetics issued Q4 2024 earnings on March 31, 2025, reporting an EPS of -$1.27, which missed the consensus estimate of -$0.34 by $0.93. Quarterly revenue was reported to be $3.40 million, below the consensus estimate of $11.10 million. With a trailing EPS of -$2.15, Opus Genetics' earnings are expected to grow next year, from ($1.22) to ($1.03) per share. Q4 2024 Earnings ResourcesQ4 2024 Earnings ReportIRD Upcoming EarningsOpus Genetics' next earnings date is estimated for Friday, May 9, 2025, based on past reporting schedules. Get Opus Genetics Earnings Alerts Want to stay updated on the latest earnings announcements and upcoming reports? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Opus Genetics and other key companies, straight to your inbox. Enter your email to sign up for newsletter Sign Up Skip Charts & View Estimated and Actual Earnings DataIRD Earnings Estimates and Actuals by QuarterEarnings Estimates and Acutals by Quarter Chart DescriptionThe chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.IRD Estimated and Actual Revenue by QuarterEstimated Revenue and Actual Revenue by Quarter Chart DescriptionThe chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter. Remove Ads Opus Genetics Analyst EPS EstimatesQuarterNumber of EstimatesLow EstimateHigh EstimateAverage EstimateQ1 20251-$0.34-$0.34-$0.34Q2 20251-$0.26-$0.26-$0.26Q3 20251-$0.26-$0.26-$0.26Q4 20251-$0.24-$0.24-$0.24FY 20254($1.10)($1.10)($1.10) Remove Ads Opus Genetics Earnings History by Quarter Custom Range 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 5 Years 10 Years Time Frame * Start Date * End Date Export to Excel DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueDetails 5/9/2025(Estimated)--------3/31/2025Q4 2024-$0.34-$1.27 -$0.93-$1.27$11.10M$3.40M11/12/2024--$0.30-$0.29+$0.01-$0.29$1.17M$3.87M Opus Genetics Earnings - Frequently Asked Questions When is Opus Genetics's earnings date? Opus Genetics has not confirmed its next earnings publication date, but the company's estimated earnings date is Friday, May 9th, 2025 based off last year's report dates. Learn more on IRD's earnings history. Did Opus Genetics beat their earnings estimates last quarter? In the previous quarter, Opus Genetics (NASDAQ:IRD) missed the analysts' consensus estimate of ($0.34) by $0.93 with a reported earnings per share (EPS) of ($1.27). Learn more on analysts' earnings estimate vs. IRD's actual earnings. How much revenue does Opus Genetics generate each year? Opus Genetics (NASDAQ:IRD) has a recorded annual revenue of $10.99 million. How much profit does Opus Genetics generate each year? Opus Genetics (NASDAQ:IRD) has a recorded net income of -$9.99 million. IRD has generated -$2.15 earnings per share over the last four quarters. What is Opus Genetics's EPS forecast for next year? Opus Genetics's earnings are expected to grow from ($1.22) per share to ($1.03) per share in the next year. More Earnings Resources from MarketBeat Related Companies Eupraxia Pharmaceuticals Earnings Date Elutia Earnings Date Fate Therapeutics Earnings Date Alector Earnings Date Seres Therapeutics Earnings Date Enanta Pharmaceuticals Earnings Date FitLife Brands Earnings Date XBiotech Earnings Date Coherus BioSciences Earnings Date SELLAS Life Sciences Group Earnings Date Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Johnson & Johnson Earnings Were More Good Than Bad—Time to Buy? Why Analysts Boosted United Airlines Stock Ahead of EarningsLamb Weston Stock Rises, Earnings Provide Calm Amidst ChaosIntuitive Machines Gains After Earnings Beat, NASA Missions AheadCintas Delivers Earnings Beat, Signals More Growth AheadNike Stock Dips on Earnings: Analysts Weigh in on What’s NextAfter Massive Post Earnings Fall, Does Hope Remain for MongoDB? Remove Ads This page (NASDAQ:IRD) was last updated on 4/16/2025 by MarketBeat.com Staff From Our PartnersCrypto’s crashing…but we’re still profitingMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredTariffs. Volatility. Fear. Here’s the Plan.Wall Street's panicking over tariffs. Volatility's back with a vengeance. If you've been glued to the he...Investors Alley | SponsoredMusk’s AI Masterplan – Our #1 AI Stock to Buy NowDid Elon Musk just set the stage for the next AI stock explosion? One 30-year Wall Street veteran thinks so...Behind the Markets | SponsoredTwo Unmistakable Patterns Return…The signs suggest we're entering one of those rare periods now. That's why Central Banks are buying gold at...Golden Portfolio | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredMusk's panic move: What the world's richest man fears is comingWhether you have modest savings of $10,000 or substantial wealth of $10 million, this information could determ...InvestorPlace | SponsoredNew “Trump” currency proposed in DCAccording to one of the most connected men in Washington… A surprising new bill was just introduced in Wash...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Opus Genetics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Opus Genetics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy IRD Stock Free IRD Stock Alerts